Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

[25] In view of these data, imatinib has become the first-line treatment for patients presenting with advanced GIST. Since the 800 mg dose causes more pronounced toxic effects but equivalent ...

The prognosis of patients with gastrointestinal stromal tumors is significantly impacted by gastrointestinal bleeding.

Patients with non-metastatic GIST treated with neoadjuvant TKIs prior to surgery experienced a benefit which led to less ...

Management trends and outcomes of appendiceal cancers: A National Cancer Database study. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not ...

The deal, which includes another $150 million in milestone payments, gives GSK an experimental treatment for a rare gastrointestinal cancer. The announcement comes as much of the biopharma world ...

The British pharma giant plans to shell out $1 billion upfront to buy the drug developer working on a lead treatment for gastrointestinal stromal tumors. As the first morning of the J.P. Morgan ...